Education Library

Alaide Chieffo, MD, discusses results from a subanalysis of women in the IMP-IT Registry in Italy.

Chuck Simonton, MD, reviews that in October 2022 the FDA accepted and closed all Impella post-approval studies for high-risk PCI, cardiogenic shock, post-cardiotomy cardiogenic shock and right heart failure.

Gregg Stone, MD, FACC, FSCAI interviews Prof. Divaka Perera, professor of cardiology at Kings College in London, UK at the European Society of Cardiology (ESC) Congress 2022 in Barcelona, Spain.

Vijay Iyer, MD, discusses important concepts being explored in the STEMI-DTU™ trial, emphasizing that unloading is not delaying treatment. 

Jay Giri, MD, discusses the pros, cons, and best uses for five types of observational database analyses.

Navin Kapur, MD, presents lessons learned in the STEMI DTU™ pilot trial in this presentation from TCT 2022. 

Seth Bilazarian, MD, and Chuck Simonton, MD, recap highlights from day one of TCT 2022 and interview Greg Stone, MD and Alaide Chieffo, MD, FESC.

This recap of highlights from day two of TCT 2022 includes interviews with Drs. Sanjit Jolly, Navin Kapur, Adrian Attinger-Toller and Taishi Hirai.

Day three highlights from TCT 2022 include several late-breaking trials and interviews with Navin Kapur, MD, and Koichi Toda, MD, PhD.

Adam Salisbury, MD, presents preliminary results from the OPTIMUM Study at TCT 2022.

At TCT 2022, Jonathan Hill, MD, presents the influential high-risk PCI trials shaping the future of ischemic heart failure therapy.

Jonathan Hill, MD, discusses influential trials in high-risk PCI that are shaping the future of ischemic heart failure therapy.

Robert Yeh, MD, discusses how we analyze data, make treatment decisions and participate in developing clinical evidence.

Aditya Bharadwaj, MD, an investigator for the RESTORE EF study, presents a case study epitomizing the results from the trial.

Mitul Patel, MD, discusses the RESTORE EF study and a successful case of improved ejection fraction with complete revascularization.